Adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery did not significantly prolong PFS or OS among women with advanced epithelial ovarian cancer, according to a single-blind, randomized study in JAMA Surgery.
However, results of a subgroup analysis showed the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery after neoadjuvant chemotherapy did reduce rates of disease recurrence and mortality among women with primary stage III or stage IV epithelial ovarian cancer, researchers wrote.
“Hyperthermic intraperitoneal